share_log

Ginkgo Bioworks | 8-K: Ginkgo Bioworks Reports First Quarter 2024 Financial Results

Ginkgo Bioworks | 8-K: Ginkgo Bioworks Reports First Quarter 2024 Financial Results

Ginkgo Bioworks | 8-K:Ginkgo Bioworks公布2024年第一季度财务业绩
美股sec公告 ·  05/09 16:08
Moomoo AI 已提取核心信息
On May 9, 2024, Ginkgo Bioworks Holdings, Inc. reported its financial results for the first quarter ended March 31, 2024. The company announced a significant restructuring plan aimed at reducing operational expenditures, including a 25% reduction in labor expenses and consolidation of facilities. The plan is expected to reduce annualized operating expenses by $200 million by mid-2025, with substantial reductions occurring in 2024. The initial phase of headcount reductions will start in the second quarter of 2024 and is anticipated to be largely completed by 2025. Ginkgo's first-quarter revenue was $38 million, a 53% decrease from the previous year, primarily due to the ramp-down of K-12 testing in its Biosecurity segment. The company also reported a loss from operations of $178 million, which included $42 million in stock-based compensation...Show More
On May 9, 2024, Ginkgo Bioworks Holdings, Inc. reported its financial results for the first quarter ended March 31, 2024. The company announced a significant restructuring plan aimed at reducing operational expenditures, including a 25% reduction in labor expenses and consolidation of facilities. The plan is expected to reduce annualized operating expenses by $200 million by mid-2025, with substantial reductions occurring in 2024. The initial phase of headcount reductions will start in the second quarter of 2024 and is anticipated to be largely completed by 2025. Ginkgo's first-quarter revenue was $38 million, a 53% decrease from the previous year, primarily due to the ramp-down of K-12 testing in its Biosecurity segment. The company also reported a loss from operations of $178 million, which included $42 million in stock-based compensation expense. Despite the decrease in revenue, the Adjusted EBITDA of $(100) million remained flat year-over-year due to a decrease in operating expenses. Ginkgo's cash and cash equivalents balance stood at $840 million at the end of the first quarter. The company's CEO, Jason Kelly, expressed disappointment in the Q1 revenues but outlined initiatives to simplify operations and reach adjusted EBITDA breakeven by the end of 2026. Ginkgo revised its 2024 revenue outlook to $170-$190 million, with Cell Engineering services revenue expected to be between $120-140 million and Biosecurity revenue anticipated to be at least $50 million.
2024年5月9日,Ginkgo Bioworks Holdings, Inc.公布了截至2024年3月31日的第一季度财务业绩。该公司宣布了一项旨在减少运营支出的重大重组计划,包括将劳动力支出减少25%和整合设施。该计划预计到2025年中期将年化运营支出减少2亿美元,并在2024年大幅削减。裁员的初始阶段将从2024年第二季度开始,预计将在2025年之前基本完成。Ginkgo的第一季度收入为3,800万美元,比上年下降了53%,这主要是由于其生物安全领域的K-12测试有所减少。该公司还报告了1.78亿美元的运营亏损,其中包括4200万美元的股票薪酬支出。尽管收入下降,但由于运营费用减少,调整...展开全部
2024年5月9日,Ginkgo Bioworks Holdings, Inc.公布了截至2024年3月31日的第一季度财务业绩。该公司宣布了一项旨在减少运营支出的重大重组计划,包括将劳动力支出减少25%和整合设施。该计划预计到2025年中期将年化运营支出减少2亿美元,并在2024年大幅削减。裁员的初始阶段将从2024年第二季度开始,预计将在2025年之前基本完成。Ginkgo的第一季度收入为3,800万美元,比上年下降了53%,这主要是由于其生物安全领域的K-12测试有所减少。该公司还报告了1.78亿美元的运营亏损,其中包括4200万美元的股票薪酬支出。尽管收入下降,但由于运营费用减少,调整后的息税折旧摊销前利润(1)亿美元同比持平。第一季度末,Ginkgo的现金和现金等价物余额为8.4亿美元。该公司首席执行官杰森·凯利对第一季度的收入表示失望,但概述了简化运营并在2026年底之前实现调整后的息税折旧摊销前利润收支平衡的举措。Ginkgo将其2024年的收入展望上调至1.7亿至1.9亿美元,细胞工程服务收入预计在1.2亿至1.4亿美元之间,生物安全收入预计至少为5000万美元。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息